Over the years, BioNet has built global research collaborations, product development and manufacturing alliances leading to the supply of billions of doses of vaccines worldwide.

BioNet is the world’s only manufacturer of recombinant pertussis-only aPgen vaccine and a recombinant TdaPgen vaccine, containing a genetically inactivated pertussis toxin (PTgen).

BioNet has been developing genetic vaccines against SARS-CoV-2 and its variant strains using nucleic acid technology platforms. Covigen is a COVID-19 DNA vaccine being evaluated in human trials in Australia. BioNet also jointly developed the manufacturing process of Chulacov-19 mRNA vaccine for clinical use. Most recently, BioNet was awarded a global innovative project in partnership with CEPI (Coalition for Epidemic Preparedness Innovations), IVI (International Vaccine Institute) and several universities, to rapidly advance the development of a pan coronavirus multiple mRNA vaccine against several types of coronaviruses.